{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:10:49Z","timestamp":1772809849880,"version":"3.50.1"},"reference-count":21,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,10,1]]},"abstract":"<jats:p>BACKGROUND\/OBJECTIVES. In 1989, the American Academy of Pediatrics and the Advisory Committee on Immunization Practices recommended that school children receive 2 doses of measles-mumps-rubella vaccine. With measles and rubella eliminated from the United States, measles-mumps-rubella vaccine adverse events have come under scrutiny, but no study has compared the reactogenicity of the first (measles-mumps-rubella vaccine dose 1) and second (measles-mumps-rubella vaccine dose 2) doses at the most common ages of administration in the United States.<\/jats:p>\n               <jats:p>METHODS. From a health maintenance organization, 3 groups of children were recruited: (1) toddlers aged 12 to 24 months receiving measles-mumps-rubella vaccine dose 1; (2) kindergartners aged 4 to 6 years receiving measles-mumps-rubella vaccine dose 2; and (3) middle schoolers aged 10 to 12 years receiving measles-mumps-rubella vaccine dose 2. From 2 weeks before measles-mumps-rubella vaccine administration until 4 weeks afterward, families recorded in diaries the occurrence of potentially common symptoms. Postvaccination symptom rates were compared with the prevaccination baseline, with significance assessed by testing incidence rate ratios estimated by Poisson regression.<\/jats:p>\n               <jats:p>RESULTS. Of 2173 children enrolled, 373 (17%) were lost to attrition, producing a study population of 1800. Compared with the prevaccination baseline, rates of fever, diarrhea, and rash were significantly elevated postvaccination among 535 toddlers receiving measles-mumps-rubella vaccine dose 1. An estimated net 95 (18%) experienced measles-mumps-rubella vaccine-associated events (median onset 5\u201310 days postvaccination, duration 2\u20135 days), with high fever (temperature \u226539.5\u00b0C) occurring in 33 (6%). None required medical attention. For 633 kindergartners and 632 middle schoolers, symptom rates were not significantly elevated after measles-mumps-rubella vaccine dose 2 compared with baseline.<\/jats:p>\n               <jats:p>CONCLUSIONS. Vaccination-associated adverse events occur in \u223c1 of every 6 toddlers receiving measles-mumps-rubella vaccine dose 1, with high fever occurring in 1 of 20. Adverse events are infrequent for measles-mumps-rubella vaccine dose 2 administered to school-aged children.<\/jats:p>","DOI":"10.1542\/peds.2006-0678","type":"journal-article","created":{"date-parts":[[2006,10,2]],"date-time":"2006-10-02T17:04:22Z","timestamp":1159808662000},"page":"1422-1430","source":"Crossref","is-referenced-by-count":41,"title":["Evaluation of Potentially Common Adverse Events Associated With the First and Second Doses of Measles-Mumps-Rubella Vaccine"],"prefix":"10.1542","volume":"118","author":[{"given":"Charles W.","family":"LeBaron","sequence":"first","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoling","family":"Bi","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Marshfield Medical Research Foundation, Marshfield, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Beck","sequence":"additional","affiliation":[{"name":"Marshfield Medical Research Foundation, Marshfield, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gargiullo","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2006,10,1]]},"reference":[{"key":"2021120822444642100_R1","unstructured":"Centers for Disease Control and Prevention. Measles prevention. Recommendations of the immunization practices advisory committee (ACIP). MMWR Morb Mortal Wkly Rep.\u20081989;38(suppl 9):1\u201318"},{"key":"2021120822444642100_R2","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Measles: reassessment of the current immunization policy. Pediatrics.\u20081989;84:1110\u20131113"},{"key":"2021120822444642100_R3","doi-asserted-by":"crossref","unstructured":"Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16\u201317 March 2000. J Infect Dis.\u20082004;189(suppl 1):S43\u2013S47","DOI":"10.1086\/377696"},{"key":"2021120822444642100_R4","unstructured":"Centers for Disease Control and Prevention. Achievements in public health: elimination of rubella and congenital rubella syndrome\u2014United States, 1969\u20132004. MMWR Morb Mortal Wkly Rep.\u20082005;54:279\u2013282"},{"key":"2021120822444642100_R5","unstructured":"Centers for Disease Control and Prevention. Measles, mumps, and rubella\u2014vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep.\u20081998;47(RR-8):1\u201357"},{"key":"2021120822444642100_R6","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mump-rubella vaccine. Pediatrics.\u20081998;101:129\u2013133","DOI":"10.1542\/peds.101.1.129"},{"key":"2021120822444642100_R7","unstructured":"Tulchinsky TH, Ginsberg GM, Abed Y, Angeles MT, Akukwe C, Bonn J. Measles control in developing and developed countries: the case for a 2-dose policy. Bull WHO.\u20081993;71:93\u2013103"},{"key":"2021120822444642100_R8","doi-asserted-by":"crossref","unstructured":"de Quadros CA, Izurieta H, Venczel L, Carrasco P. Measles eradication in the Americas: progress to date. J Infect Dis.\u20082004;189(suppl 1):S227\u2013S235","DOI":"10.1086\/377741"},{"key":"2021120822444642100_R9","doi-asserted-by":"crossref","unstructured":"Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet.\u20081998;351:356\u2013361","DOI":"10.1016\/S0140-6736(97)04334-1"},{"key":"2021120822444642100_R10","doi-asserted-by":"crossref","unstructured":"Jansen VAA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science.\u20082003;301:804","DOI":"10.1126\/science.1086726"},{"key":"2021120822444642100_R11","doi-asserted-by":"crossref","unstructured":"Peltola H, Heinonen OP. Frequency of true adverse reactions to measles,-mumps-rubella vaccine. Lancet.\u20081986;i:939\u2013942","DOI":"10.1016\/S0140-6736(86)91044-5"},{"key":"2021120822444642100_R12","doi-asserted-by":"crossref","unstructured":"Chen RT, Moses JM, Markowitz LE, Orenstein WA. Adverse events following measles-mumps-rubella vaccinations in college students. Vaccine.\u20081991;9:297\u2013299","DOI":"10.1016\/0264-410X(91)90053-9"},{"key":"2021120822444642100_R13","doi-asserted-by":"crossref","unstructured":"Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years of age: a comparison of adverse clinical events after immunization in the vaccine safety datalink project. Pediatrics.\u20081997;100:767\u2013771","DOI":"10.1542\/peds.100.5.767"},{"key":"2021120822444642100_R14","doi-asserted-by":"crossref","unstructured":"Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics. 2000;106(5). Available at: www.pediatrics.org\/cgi\/content\/full\/106\/5\/e62","DOI":"10.1542\/peds.106.5.e62"},{"key":"2021120822444642100_R15","doi-asserted-by":"crossref","unstructured":"Gothfors L, Bergstrom E, Backman M. Immunogenicity and reactogenicity of a new measles, mumps, and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis.\u20082001;33:545\u2013549","DOI":"10.1080\/00365540110026593"},{"key":"2021120822444642100_R16","doi-asserted-by":"crossref","unstructured":"Kaye JA, Meloro-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. Br Med J.\u20082001;322:460\u2013463","DOI":"10.1136\/bmj.322.7284.460"},{"key":"2021120822444642100_R17","doi-asserted-by":"crossref","unstructured":"Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA.\u20082004;292:351\u2013357","DOI":"10.1001\/jama.292.3.351"},{"key":"2021120822444642100_R18","doi-asserted-by":"crossref","unstructured":"Chen RT, Glasser JW, Rhodes PH, et al. Vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics.\u20081997;99:765\u2013773","DOI":"10.1542\/peds.99.6.765"},{"key":"2021120822444642100_R19","unstructured":"US Census Bureau. County and City Data Book: 2000, 13th ed. Washington, DC: US Census Bureau; 2001:64\u201365"},{"key":"2021120822444642100_R20","doi-asserted-by":"crossref","unstructured":"Kohl KS, Bonhoeffer J, Chen R, et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf.\u20082003;12:1\u20136","DOI":"10.1002\/pds.851"},{"key":"2021120822444642100_R21","doi-asserted-by":"crossref","unstructured":"Marcy SM, Kohl KS, Dagan R, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine.\u20082004;22:551\u2013556","DOI":"10.1016\/j.vaccine.2003.09.007"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/4\/1422\/1116324\/zpe01006001422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/4\/1422\/1116324\/zpe01006001422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T02:35:21Z","timestamp":1639017321000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/118\/4\/1422\/69096\/Evaluation-of-Potentially-Common-Adverse-Events"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,1]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,10,1]]},"published-print":{"date-parts":[[2006,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-0678","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,1]]}}}